3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”

Alzheimer’s disease (AD) transgenic mice have been used as a standard AD model for basic mechanistic studies and drug discovery. These mouse models showed symbolic AD pathologies including β-amyloid (Aβ) plaques, gliosis and memory deficits but failed to fully recapitulate AD pathogenic cascades including robust phospho tau (p-tau) accumulation, clear neurofibrillary tangles (NFTs) and neurodegeneration, solely driven by familial AD (FAD) mutation(s). Recent advances in human stem cell and three-dimensional (3D) culture technologies made it possible to generate novel 3D neural cell culture models that recapitulate AD pathologies including robust Aβ deposition and Aβ-driven NFT-like tau pathology. These new 3D human cell culture models of AD hold a promise for a novel platform that can be used for mechanism studies in human brain-like environment and high-throughput drug screening (HTS). In this review, we will summarize the current progress in recapitulating AD pathogenic cascades in human neural cell culture models using AD patient-derived induced pluripotent stem cells (iPSCs) or genetically modified human stem cell lines. We will also explain how new 3D culture technologies were applied to accelerate Aβ and p-tau pathologies in human neural cell cultures, as compared the standard two-dimensional (2D) culture conditions. Finally, we will discuss a potential impact of the human 3D human neural cell culture models on the AD drug-development process. These revolutionary 3D culture models of AD will contribute to accelerate the discovery of novel AD drugs.

[1]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[2]  Basavaraj Hooli,et al.  A three-dimensional human neural cell culture model of Alzheimer’s disease , 2014, Nature.

[3]  Hiroyuki Miyoshi,et al.  Self-formation of functional adenohypophysis in three-dimensional culture , 2011, Nature.

[4]  T. Bayer,et al.  Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice , 2003, Experimental Neurology.

[5]  N. Kotov,et al.  Three-dimensional cell culture matrices: state of the art. , 2008, Tissue engineering. Part B, Reviews.

[6]  B. de Strooper,et al.  Loss‐of‐function presenilin mutations in Alzheimer disease , 2007, EMBO reports.

[7]  J. Hardy,et al.  The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.

[8]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[9]  L. Tsai,et al.  Self-Organizing 3D Human Neural Tissue Derived from Induced Pluripotent Stem Cells Recapitulate Alzheimer’s Disease Phenotypes , 2016, PloS one.

[10]  J. Weuve,et al.  2016 Alzheimer's disease facts and figures , 2016 .

[11]  M. Frech,et al.  Differentiation of Human Neural Progenitor Cells in Functionalized Hydrogel Matrices , 2012, BioResearch open access.

[12]  Young Hye Kim,et al.  A 3D human neural cell culture system for modeling Alzheimer's disease , 2015, Nature Protocols.

[13]  D. Nicholson,et al.  Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s disease , 2016, Acta Neuropathologica.

[14]  N. Cutler,et al.  Review of the next generation of Alzheimer's disease therapeutics: challenges for drug development , 2001, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  J. Fisher,et al.  Neural differentiation of pluripotent cells in 3D alginate-based cultures. , 2014, Biomaterials.

[16]  Young Hye Kim,et al.  Alzheimer's in 3D culture: Challenges and perspectives , 2015, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  R. J. Kelleher,et al.  The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.

[18]  A. Dinnyés,et al.  Establishment of PSEN1 mutant induced pluripotent stem cell (iPSC) line from an Alzheimer's disease (AD) female patient. , 2016, Stem cell research.

[19]  G. Schellenberg,et al.  Regulation of tau isoform expression and dementia. , 2005, Biochimica et biophysica acta.

[20]  Michelle C. LaPlaca,et al.  Three-Dimensional Neuronal Cultures , 2010 .

[21]  Ronan M. T. Fleming,et al.  Differentiation of neuroepithelial stem cells into functional dopaminergic neurons in 3D microfluidic cell culture. , 2015, Lab on a chip.

[22]  B. Strooper,et al.  Lessons from a Failed γ-Secretase Alzheimer Trial , 2014, Cell.

[23]  J. Mertens,et al.  Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation. , 2012, The American journal of pathology.

[24]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[25]  Han-Kyu Lee,et al.  Three Dimensional Human Neuro-Spheroid Model of Alzheimer’s Disease Based on Differentiated Induced Pluripotent Stem Cells , 2016, PloS one.

[26]  Kristopher L. Nazor,et al.  Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.

[27]  R. Shigemoto,et al.  Structural involvement of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology , 2003, Neuroscience Letters.

[28]  M. Araúzo-Bravo,et al.  Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein , 2015, Stem cell reports.

[29]  D. Selkoe,et al.  The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. , 2014, Human molecular genetics.

[30]  M. Spillantini,et al.  Frontotemporal Dementia with Tau Pathology , 2007, Neurodegenerative Diseases.

[31]  J. C. Love,et al.  Single-Cell Detection of Secreted Aβ and sAPPα from Human IPSC-Derived Neurons and Astrocytes , 2016, The Journal of Neuroscience.

[32]  K. Duff,et al.  Progress in the modeling of neurodegenerative diseases in transgenic mice , 2001, Current opinion in neurology.

[33]  Kun Zhang,et al.  The presenilin-1 ΔE9 mutation results in reduced γ-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. , 2013, Cell reports.

[34]  A. Kriegstein,et al.  Cerebral Organoids in a Dish: Progress and Prospects , 2013, Cell.

[35]  Colin J. Mahoney,et al.  Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT , 2015, Human molecular genetics.

[36]  R. Tanzi,et al.  Recapitulating amyloid β and tau pathology in human neural cell culture models: clinical implications. , 2015, US neurology.

[37]  David L Kaplan,et al.  Bioengineered functional brain-like cortical tissue , 2014, Proceedings of the National Academy of Sciences.

[38]  P. Adlard,et al.  Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging , 2009, Neurobiology of Aging.

[39]  S. Itohara,et al.  Single App knock-in mouse models of Alzheimer's disease , 2014, Nature Neuroscience.

[40]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[41]  Ben A. Barres,et al.  Complement and microglia mediate early synapse loss in Alzheimer mouse models , 2016, Science.

[42]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[43]  Jean-Louis Viovy,et al.  A review of microfabrication and hydrogel engineering for micro-organs on chips. , 2014, Biomaterials.

[44]  R. Livesey A human stem cell model of early Alzheimer's disease pathology in Down syndrome , 2012, Alzheimer's & Dementia.

[45]  J. Thomson,et al.  Human Induced Pluripotent Stem Cell Derived Neuronal Cells Cultured on Chemically-Defined Hydrogels for Sensitive In Vitro Detection of Botulinum Neurotoxin , 2015, Scientific Reports.

[46]  A. Levey,et al.  Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities , 2007, The EMBO journal.

[47]  F. Edwards,et al.  Differential development of neuronal physiological responsiveness in two human neural stem cell lines , 2007, BMC Neuroscience.

[48]  K. Blennow,et al.  APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons , 2015, Cell reports.

[49]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[50]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[51]  M. Frech,et al.  Effect of 3D-scaffold formation on differentiation and survival in human neural progenitor cells , 2010, Biomedical engineering online.

[52]  R. Vassar,et al.  Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer’s disease , 2016, Neuroscience & Biobehavioral Reviews.

[53]  R. Yan Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs , 2016, Translational Neurodegeneration.

[54]  Jianping Fu,et al.  On human pluripotent stem cell control: The rise of 3D bioengineering and mechanobiology. , 2015, Biomaterials.

[55]  Roger D. Kamm,et al.  Modeling the Blood-Brain Barrier in a 3D triple co-culture microfluidic system , 2015, 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[56]  A. Dinnyés,et al.  Establishment of induced pluripotent stem cell (iPSC) line from an 84-year old patient with late onset Alzheimer's disease (LOAD). , 2016, Stem cell research.

[57]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[58]  Ottavio Arancio,et al.  Characterization and Molecular Profiling of PSEN1 Familial Alzheimer's Disease iPSC-Derived Neural Progenitors , 2014, PloS one.

[59]  I. Lombardo,et al.  The efficacy of RVT-101, a 5-ht6 receptor antagonist, as an adjunct to donepezil in adults with mild-to-moderate Alzheimer’s disease: Completer analysis of a phase 2b study , 2015, Alzheimer's & Dementia.

[60]  L. Liotta,et al.  Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. , 1982, Biochemistry.

[61]  Bradley T. Hyman,et al.  Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes , 2016, Proceedings of the National Academy of Sciences.

[62]  R. Vassar BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[63]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[64]  Y. Uchida,et al.  The role of calsyntenin‐3 in dystrophic neurite formation in Alzheimer's disease brain , 2016, Geriatrics & gerontology international.

[65]  J. Kessler,et al.  Stem cell derived basal forebrain cholinergic neurons from Alzheimer’s disease patients are more susceptible to cell death , 2014, Molecular Neurodegeneration.

[66]  Qinying Wang,et al.  Direct Conversion of Normal and Alzheimer's Disease Human Fibroblasts into Neuronal Cells by Small Molecules. , 2015, Cell Stem Cell.

[67]  J. Schneider,et al.  Central role for PICALM in amyloid–β blood–brain barrier transcytosis and clearance , 2015, Nature Neuroscience.

[68]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[69]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[70]  J. Trojanowski,et al.  The Levels of Soluble versus Insoluble Brain Aβ Distinguish Alzheimer's Disease from Normal and Pathologic Aging , 1999, Experimental Neurology.

[71]  Matthew Trotter,et al.  Capture of Neuroepithelial-Like Stem Cells from Pluripotent Stem Cells Provides a Versatile System for In Vitro Production of Human Neurons , 2012, PloS one.

[72]  X. Zhu,et al.  Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer’s disease , 2015, Molecular Psychiatry.

[73]  R. Armstrong A critical analysis of the 'amyloid cascade hypothesis'. , 2014, Folia neuropathologica.

[74]  P. Whitehouse,et al.  Alteration of neuritic cytoarchitecture in Alzheimer disease. , 1989, Progress in clinical and biological research.

[75]  Madeline A. Lancaster,et al.  Cerebral organoids model human brain development and microcephaly , 2013, Nature.

[76]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[77]  H. Okano,et al.  Modeling familial Alzheimer's disease with induced pluripotent stem cells. , 2011, Human molecular genetics.

[78]  James Adjaye,et al.  Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer’s disease donor as a model for investigating AD-associated gene regulatory networks , 2015, BMC Genomics.

[79]  Antonia Gutierrez,et al.  Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer’s mice hippocampus , 2011, Acta Neuropathologica.

[80]  Daniel J. Gaffney,et al.  Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with MAPT mutations , 2015, Brain : a journal of neurology.

[81]  A. Dinnyés,et al.  Establishment of induced pluripotent stem cell (iPSC) line from a 75-year old patient with late onset Alzheimer's disease (LOAD). , 2016, Stem cell research.

[82]  A. Dinnyés,et al.  Establishment of induced pluripotent stem cell (iPSC) line from a 63-year old patient with late onset Alzheimer's disease (LOAD). , 2016, Stem cell research.

[83]  K. Ando,et al.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. , 2011, The American journal of pathology.

[84]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[85]  Rudolph E. Tanzi,et al.  Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. , 2014, JAMA neurology.

[86]  B. de Strooper,et al.  The amyloid cascade hypothesis: are we poised for success or failure? , 2016, Journal of neurochemistry.

[87]  John Q Trojanowski,et al.  The role of tau in Alzheimer's disease. , 2002, The Medical clinics of North America.

[88]  R. Tanzi A brief history of Alzheimer's disease gene discovery. , 2012, Journal of Alzheimer's disease : JAD.

[89]  Marc Tessier-Lavigne,et al.  Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9 , 2016, Nature.

[90]  G. Waldemar,et al.  Generation of induced pluripotent stem cells (iPSCs) from an Alzheimer's disease patient carrying an A79V mutation in PSEN1. , 2016, Stem cell research.

[91]  J. Chin,et al.  Selecting a mouse model of Alzheimer's disease. , 2010, Methods in molecular biology.

[92]  G. Lajoie,et al.  Matrigel: A complex protein mixture required for optimal growth of cell culture , 2010, Proteomics.

[93]  Fei Liu,et al.  Tau in Alzheimer disease and related tauopathies. , 2010, Current Alzheimer research.

[94]  Han-Kyu Lee,et al.  Lab resource : stem cell line Peripheral blood mononuclear cell-converted induced pluripotent stem cells ( iPSCs ) from an early onset Alzheimer ' s patient , 2016 .

[95]  Anna Ochałek,et al.  Establishment of induced pluripotent stem cell (iPSC) line from a 57-year old patient with sporadic Alzheimer's disease. , 2016, Stem cell research.

[96]  Padma Gopalan,et al.  Surface functionalization and dynamics of polymeric cell culture substrates. , 2016, Current opinion in biotechnology.

[97]  Christopher M Ward,et al.  Familial Alzheimer's disease modelling using induced pluripotent stem cell technology. , 2014, World journal of stem cells.

[98]  R. Tanzi,et al.  Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses , 2008, Nature Reviews Neuroscience.

[99]  G. Sethuraman,et al.  Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings , 2014, Current medical research and opinion.

[100]  Katsuhiro Yoshikawa,et al.  Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. , 2013, Cell stem cell.

[101]  Jing Zhao,et al.  Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells , 2015, Molecular Neurodegeneration.

[102]  Nic D. Leipzig,et al.  3D Differentiation of Neural Stem Cells in Macroporous Photopolymerizable Hydrogel Scaffolds , 2012, PloS one.

[103]  J. Trojanowski,et al.  Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. , 2011, Cold Spring Harbor perspectives in medicine.